91 filings
Page 4 of 5
8-K
x6zg7lut 38y
3 Nov 15
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
rtd044onbwc7w41y
7 Aug 15
Departure of Directors or Certain Officers
12:00am
8-K
ys8dkoe7xgm7jw3
27 Apr 15
Departure of Directors or Certain Officers
12:00am
8-K
4lfvhojny7nemz0sck1
31 Mar 15
Entry into a Material Definitive Agreement
12:00am
8-K
pyoy0y5
29 Dec 14
Departure of Directors or Certain Officers
12:00am
8-K
vl72 l77lkd20ol9hq37
24 Oct 14
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
12:00am
8-K
vxtl akyihbcm4hmo5
24 Sep 14
Cellceutix Provides Update to Shareholders
12:00am
8-K
pc40k1x
2 Sep 14
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
12:00am
8-K
osom5g gb
28 Oct 13
Cellceutix Enters into New $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
12:00am
8-K
igv0qcx khv6
9 Sep 13
Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
12:00am
8-K
ymg66s 5pseig2o4tcr9
5 Jun 13
Changes in Registrant's Certifying Accountant
12:00am
8-K
c2qws721x8h390 ca
8 Mar 13
Unregistered Sales of Equity Securities
12:00am
8-K
6q7lzg
4 Mar 13
Cellceutix Signs with Leading Cancer Center For Licensing New Drug
12:00am
8-K
gw2n89lllmcn8q6
8 Jan 13
Termination of a Material Definitive Agreement
12:00am
8-K
b0w6rhmikqza cwk1
27 Dec 12
Regulation FD Disclosure
12:00am
8-K
ko564n9yt
26 Dec 12
Cellceutix Comments on New York Times Article Heralding p53 Drugs as the New Age in Cancer Research
12:00am
8-K
40xevsl
10 Dec 12
Entry into a Material Definitive Agreement
12:00am
8-K
lmmlpeb2 9azaabugk
29 Jun 12
Unregistered Sales of Equity Securities
12:00am
8-K
4osk3k
22 Jun 12
Cellceutix Approved By FDA to Proceed with Clinical Trials on Novel Cancer Drug
12:00am
8-K
jhd3u1
10 May 12
Unregistered Sales of Equity Securities
12:00am